High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial
Sigurgeirsson B, Browning J, Tyring S, Szepietowski J, Rivera-Diaz R, Effendy I, Keefe D, Bruin G, Paguet B, Fu R, Hampele I, et al. (2021)
Arthritis & Rheumatology 73(Suppl. 9): 448-449.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Sigurgeirsson, Bardur;
Browning, John;
Tyring, Stephen;
Szepietowski, Jacek;
Rivera-Diaz, Raquel;
Effendy, IsaakUniBi ;
Keefe, Deborah;
Bruin, Gerard;
Paguet, Bertrand;
Fu, Rong;
Hampele, Isabelle;
Reinhardt, Maximilian
Erscheinungsjahr
2021
Serien- oder Zeitschriftentitel
Arthritis & Rheumatology
Band
73
Ausgabe
Suppl. 9
Seite(n)
448-449
Konferenz
ACR Convergence 2021
Konferenzort
Virtuell
Konferenzdatum
2021-11-05 – 2021-11009
ISSN
2326-5191
eISSN
2326-5205
Page URI
https://pub.uni-bielefeld.de/record/2968740
Zitieren
Sigurgeirsson B, Browning J, Tyring S, et al. High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial. Arthritis & Rheumatology . 2021;73(Suppl. 9):448-449.
Sigurgeirsson, B., Browning, J., Tyring, S., Szepietowski, J., Rivera-Diaz, R., Effendy, I., Keefe, D., et al. (2021). High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial. Arthritis & Rheumatology , 73(Suppl. 9), 448-449. https://doi.org/10.1002/art.41966
Sigurgeirsson, Bardur, Browning, John, Tyring, Stephen, Szepietowski, Jacek, Rivera-Diaz, Raquel, Effendy, Isaak, Keefe, Deborah, et al. 2021. “High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial”, Arthritis & Rheumatology , 73 (Suppl. 9): 448-449.
Sigurgeirsson, B., Browning, J., Tyring, S., Szepietowski, J., Rivera-Diaz, R., Effendy, I., Keefe, D., Bruin, G., Paguet, B., Fu, R., et al. (2021). High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial. Arthritis & Rheumatology 73, 448-449.
Sigurgeirsson, B., et al., 2021. High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial. Arthritis & Rheumatology , 73(Suppl. 9), p 448-449.
B. Sigurgeirsson, et al., “High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial”, Arthritis & Rheumatology , vol. 73, 2021, pp. 448-449.
Sigurgeirsson, B., Browning, J., Tyring, S., Szepietowski, J., Rivera-Diaz, R., Effendy, I., Keefe, D., Bruin, G., Paguet, B., Fu, R., Hampele, I., Reinhardt, M.: High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial. Arthritis & Rheumatology . 73, 448-449 (2021).
Sigurgeirsson, Bardur, Browning, John, Tyring, Stephen, Szepietowski, Jacek, Rivera-Diaz, Raquel, Effendy, Isaak, Keefe, Deborah, Bruin, Gerard, Paguet, Bertrand, Fu, Rong, Hampele, Isabelle, and Reinhardt, Maximilian. “High Efficacy, Safety, and Tolerability of Secukinumab Injection with 2 mL Auto-injector (300 Mg) in Adult Patients with Moderate to Severe Plaque Psoriasis: 52-week Results from MATURE, a Randomised, Placebo-controlled Trial”. Arthritis & Rheumatology 73.Suppl. 9 (2021): 448-449.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in